Alkem Laboratories Ltd Sector Top 20
Pharmaceutical company operating in the generic and speciality pharmaceutical sector with a footprint in 40 countries.
Valuation
Returns
Per share
Growth · year on year
Ownership
Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.
How this score is calculated
| Measure | Value | Scores | Source |
|---|---|---|---|
| P/E What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall. Computed on a different basis this reads 30.35, which would score 50/100. Scored on the figure shown. |
18.36 | 75/100 | BSE |
| P/B Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons. |
4.44 | 50/100 | Market data |
| ROE Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business. |
16.60 | 75/100 | Market data |
| ROCE Return on capital employed — the same idea including debt, so it is harder to flatter with leverage. |
18.95 | 75/100 | Market data |
| Profit growth Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do. |
4.57 | 25/100 | Market data |
| Sales growth Year-on-year growth in revenue. |
9.65 | 50/100 | Market data |
| Revenue growth · filed Year-on-year revenue growth computed from the fiscal-year figures we filed ourselves and cited to a real disclosure, not a market data feed. |
13.50 | 75/100 | Atlas |
| Profit trend · filed Whether profit is improving, from the same filed figures. A swing from loss to profit scores highest; a swing from profit into loss scores lowest; a narrowing loss still scores better than a widening one. |
6.10 | 25/100 | Atlas |
| Promoter holding How much of the company its founders and controlling group still own. Higher usually means their money moves with yours. |
49.70 | 75/100 | Market data |
The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.
Alkem Laboratories Ltd: Funding Rounds
No funding rounds tracked for Alkem Laboratories Ltd yet.
News on Alkem Laboratories Ltd
-
16 Sep 2026
NeuCeno Brings Cenobamate to India
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free ValidationFAQs on Alkem Laboratories Ltd
What does Alkem Laboratories Ltd do?
Pharmaceutical company operating in the generic and speciality pharmaceutical sector with a footprint in 40 countries.